[Progress in the treatment of hepatitis B and C co-infection in HIV patients].
HIV patients co-infected with hepatitis B can be successfully treated with lamivudine, adefovir and tenofovir. However, in a variable portion of patients resistance against these agents may occur. The application of pegylated interferon alfa in combination with ribavirin represents an advance in the treatment of hepatitis C and HIV co-infected patients. In patients with markers of advanced liver cirrhosis a substantial risk for the development of hepatic decompensation under interferon-based therapy was observed. Antiretroviral therapy with didanosine may further enhance this risk.
Mauss
S
S
Zentrum für HIV und Hepatogastroenterologie, Düsseldorf. maussst@compuserve.com
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000401:mortality; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015897:Comorbidity; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000401:mortality; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000009:adverse effects; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D015996:Survival Rate
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a
HIV-Patienten mit Hepatitis-B- und -C-Koinfektion. Therapeutischer Fortschritt zeichnet sich ab.